Sanara MedTech (NASDAQ:SMTI) Announces Quarterly Earnings Results

Sanara MedTech (NASDAQ:SMTI) posted its quarterly earnings results on Monday. The company reported ($0.18) EPS for the quarter, beating analysts’ consensus estimates of ($0.28) by $0.10, Zacks reports. Sanara MedTech had a negative net margin of 10.71% and a negative return on equity of 19.86%.

Sanara MedTech Stock Up 6.2 %

Shares of Sanara MedTech stock opened at $35.69 on Tuesday. Sanara MedTech has a twelve month low of $26.00 and a twelve month high of $39.08. The company has a quick ratio of 2.02, a current ratio of 2.23 and a debt-to-equity ratio of 0.76. The company’s 50 day moving average is $34.43 and its 200 day moving average is $33.84. The company has a market cap of $311.97 million, a price-to-earnings ratio of -36.05 and a beta of 1.37.

Wall Street Analyst Weigh In

SMTI has been the topic of several recent analyst reports. HC Wainwright reiterated a “buy” rating and set a $50.00 target price on shares of Sanara MedTech in a research note on Thursday, January 23rd. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $44.00 price objective on shares of Sanara MedTech in a research report on Wednesday, January 22nd.

Sanara MedTech Company Profile

Sanara MedTech Inc, a medical technology company, develops, markets, and distributes surgical, wound, and skincare products and services to physicians, hospitals, clinics, and post-acute care settings in the United States. The company offers CellerateRX Surgical, a medical hydrolysate of Type I bovine collagen indicated for the management of surgical, traumatic, and partial- and full-thickness wounds, as well as first- and second-degree burns; and HYCOL, a medical hydrolysate of Type I bovine collagen intended for the management of full and partial thickness wounds, including pressure ulcers, venous and arterial leg ulcers, and diabetic foot ulcers.